LLY Days sales outstanding
Days sales outstanding at Lilly (Eli) rose to 99.5 days in fiscal 2025, the highest in the 5 years reported, from 89.2 days in 2024.
Year-end receivables divided by total revenue, times 365. Both inputs as filed.
SOURCE: us-gaap:AccountsReceivableNetCurrent + us-gaap:Revenues · EDGAR CompanyFacts · CIK 59478 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Receivables | Revenue | DSO |
|---|---|---|---|
| FY2025 | $17.8B | $65.2B | 99.5 days |
| FY2024 | $11.0B | $45.0B | 89.2 days |
| FY2023 | $9.1B | $34.1B | 97.2 days |
| FY2022 | $6.9B | $28.5B | 88.2 days |
| FY2021 | $6.7B | $28.3B | 86.0 days |
Cross-checks touching this measure FROM THE FILING REVIEW
◐ PARTLYrevenue growth
The quote contains no checkable figures; the lines it references are shown, and nothing on this page confirms or contradicts it.
FY2025 10-K · FULL RECONCILIATION →◐ PARTLYgross margin
The quote contains no checkable figures; the lines it references are shown, and nothing on this page confirms or contradicts it.
FY2025 10-K · FULL RECONCILIATION →✗ RED FLAGInventory vs revenue pace
Inventory grew +36.4pp faster than revenue. Above the 15pp threshold. Management's own account touching these lines appears in the "revenue growth" claim on this page (partial); this page has not independently verified it.
FY2025 10-K · FULL RECONCILIATION →◐ WATCHReceivables pace
Days sales outstanding moved +10.3 days. Carried as watch; this page verifies no stated cause.
FY2025 10-K · FULL RECONCILIATION →More SAME DATA, OTHER VIEWS
Days sales outstanding across coverage → · LLY company view →
Revenue · Net income · Operating cash flow · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.